drugset / Trial / NCT03006614
PERS Genetic Model Assistant Decision-making System of Neoadjuvant Chemotherapy for Breast Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
This study aims to explore new PERS prediction model can improve the pathological complete response rate of neoadjuvant chemotherapy of breast cancer and disease-free survival.
Timeline
- Start
- 2016-04
- Primary completion
- 2018-03
- Completion
- 2023-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CAP | Unknown | 1000 mg/m2 | — |
| Comparator | CTX | Unknown | 600 mg/m2 | — |
| Subject | DDP | Unknown | 70 mg/m2 | — |
| Comparator | EPI | Unknown | 90 mg/m2 | — |
| Subject | GEM | Unknown | 1000 mg/m2 | — |
| Subject | H | Unknown | — | — |
| Subject | NVB | Unknown | 25 mg/m2 | Intravenous |
| Comparator | T | Unknown | 75 mg/m2 | — |